Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential

Andrea Negro1,2
Angela Koverech2,3
Paolo Martelletti1,2

1Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy; 2Department of Internal and Emergency Medicine, Regional Referral Headache Centre, Sant’Andrea Hospital, Rome, Italy; 3Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University, Rome, Italy

Abstract: Migraine is an important socioeconomic burden and is ranked the sixth cause of years of life lost because of disability in the general population and the third cause of years of life lost in people younger than 50 years. The cornerstone of pharmacological treatment is represented by the acute therapy. The serotonin (5-hydroxytryptamine [5-HT]) receptor subtype 1B/1D agonists, called triptans, are nowadays the first-line acute therapy for patients who experience moderate-to-severe migraine attacks. Unfortunately, a high percentage of patients are not satisfied with this acute treatment, either for lack of response or side effects. Moreover, their mechanism of action based on vasoconstriction makes them unsuitable for patients with previous cardio- and cerebrovascular diseases and for those with uncontrolled hypertension. Since the introduction of triptans, no other acute drug class has passed all developmental stages. The research for a new drug lacking vasoconstrictive effects led to the development of lasmiditan, a highly selective 5-HT1F receptor agonist with minimized interactions with other 5-HT receptor subtypes. Lasmiditan is considered to be the first member of a new drug category, the neurally acting anti-migraine agent (NAAMA). Phase II and III trials had shown superiority compared to placebo and absence of typical triptan-associated adverse events (AEs). Most of the AEs were related to the central nervous system, depending on the high permeability through the blood–brain barrier and mild to moderate severity. The results of ongoing long-term Phase III trials will determine whether lasmiditan will become available in the market, and then active triptan comparator studies will assess patients’ preference. Future studies could then explore the safety during pregnancy and breastfeeding or the risk that overuse of lasmiditan leads to medication overuse headache.

Keywords: migraine, acute treatment, lasmiditan, 5-HT1F agonists

Introduction

Migraine is a primary headache disorder characterized by moderate-to-severe headache attacks lasting 4–72 hours with unilateral location and pulsating quality, aggravated by movement or causing avoidance of routine physical activity and associated with nausea and/or vomiting, photophobia, and phonophobia.1 Migraine is an important socioeconomic burden and is ranked the sixth cause of years of life lost because of disability in the general population and the third cause of years of life lost in people younger than 50 years.2–5

Migraine is an episodic disorder, but its frequency during the lifetime can fluctuate back and forth from a low to a high pattern. Each year, ~3% of patients with episodic migraine develop new-onset chronic migraine (CM), with headache occurring ≥15 days/month (for >3 months with at least eight attacks having migraine features).1
When the frequency of the attacks is four or more per month, a preventative therapy with one or more of the following pharmacological classes is required: antihypertensive agents (e.g., β-blockers, calcium channel blockers, angiotensin-converting enzyme [ACE] inhibitors, aldosterone receptor blockers), antiepileptic drugs (e.g., topiramate, divalproex sodium), and tricyclic antidepressants (e.g., amitriptyline, nortriptyline). Botox® (onabotulinumtoxinA) is indicated as effective and safe drugs for the vast majority of migraine patients. Despite a similar molecular structure, limited benefit from administration of triptans, while others complain of participants in randomized clinical trials (RCTs) do not benefit from administration of triptans, while others complain about their lack of consistency over time. Likewise, pain freedom rate at 2 hours after administration of triptans ranges from 12% (frovatriptan 2.5 mg) to 40% (rizatriptan 10 mg).

The cornerstone of pharmacological treatment is represented by the acute therapy, aimed to abort attacks and lead to a prompt relief from pain. Migraine acute therapy is based on nonspecific (analgesics and nonsteroidal anti-inflammatory drugs [NSAIDs]) or specific (triptans and ergot derivatives) drugs. The choice may be based on a stratified care approach (i.e., depending on migraine severity and other clinical factors) or on the step care management (i.e., if the response to analgesics is not sufficient, patients might receive specific drugs).

Current acute treatments
Triptans (5-HT1B/1D receptor agonists)
The serotonin (5-hydroxytryptamine [5-HT]) receptor subtype 1B/1D agonists (triptans) are nowadays the first-line acute therapy for patients who experience moderate-to-severe migraine attacks. Since the introduction of Sumavel DosePro® (sumatriptan) in 1991, other triptan compounds with improved pharmacokinetic properties, efficacy, and safety were developed. They are more lipophilic than sumatriptan and consequently more capable to penetrate the blood–brain barrier (BBB), thereby reaching their site of action more readily. Currently, seven triptans are available; in order of release, they are as follows: sumatriptan, zolmitriptan, rizatriptan, naratriptan, eletriptan, almotriptan, and frovatriptan.

All triptans are superior to placebo and can be considered as effective and safe drugs for the vast majority of migraine patients. Despite a similar molecular structure, each triptan has its own pharmacokinetic and pharmacodynamic profile. Some of them have characteristics similar to sumatriptan, displaying a rapid dose-dependent efficacy with a higher risk of adverse effects (AEs), while others have a slower relieving effect on migraine symptoms but a more prolonged duration of action and less recurrence of migraine attacks.

Safety and contraindications
Triptans bind mostly to 5-HT1B and 5-HT1D receptors within cerebral blood vessels (endothelium), leading to a rather selective vasoconstriction and inhibiting the release of neurogenic inflammatory mediators such as calcitonin gene-related peptide (CGRP).

The 5-HT1B/1D receptors are also present on coronary and limb arteries. Accordingly, triptan administration causes a reduction in coronary artery diameter and a brief constriction of limb arteries. Although these minor constrictions are unlikely to cause symptoms and the risk for cardiovascular events is very low in normal patients, triptans may possibly cause ischemia in those with coronary disease. Rare cases of stroke, myocardial infarction, and arrhythmia have been reported in temporal relation to use of triptans. For this reason, patients with myocardial infarction, coronary artery disease, stroke, uncontrolled hypertension, and vasculitis cannot use triptans. In addition, for patients with hemiplegic migraine or with prolonged migraine aura, as well as for pregnant women, triptans are not entirely recommended.

Although they are safe drugs, class-related side effects (e.g., chest tightness and throat discomfort, muscle pain, and paresthesia) are reported by up to 24% of patients using oral triptans and by 40% of patients using subcutaneous formulation. For instance, injectable formulation may be slightly uncomfortable at the site of injection and can potentiate the events known as triptan sensation.

Migraineurs with four or more attacks per months need a preventative treatment. The frequent presence of comorbidities should drive the choice of a preventive drug, in order to reduce the medication intake and increase the efficacy for both the disorders. Consequently, choosing the safest acute therapy during migraine prophylactic treatment needs pharmacokinetic and pharmacodynamic considerations.

For example, triptans are contraindicated in patients with comorbid depression taking serotonin reuptake inhibitors due to the theoretical possibility of serotoninergic syndrome.

Limitations
An Australian pharmacoepidemiological study showed that total triptan use has increased at an average annual rate of 112% over the 18-year period. Besides, only a minority of migraine patients use the specific antimigraine drug triptans (10% in Denmark, 17% in Italy, and 35% in France). The most probable reason is the relatively low efficacy. Over 35% of participants in randomized clinical trials (RCTs) do not benefit from administration of triptans, while others complain about their lack of consistency over time. Likewise, pain freedom rate at 2 hours after administration of triptans ranges from 12% (frovatriptan 2.5 mg) to 40% (rizatriptan 10 mg).

More indeed, the American Migraine Prevalence and Prevention Study found that 40% of episodic migraine patients...
have unmet treatment needs, with dissatisfaction with current migraine medication (15%) and headache-related disability (19%) as the most frequent complaints. Therefore, over the past 5 years, most clinical studies investigated how to improve triptan therapy, increasing efficacy and decreasing adverse reactions. The two principal lines of research were the combination therapy and novel triptan administration routes and devices.

Combination therapy
Most of the clinical trials studied combinations of triptans with NSAIDs, particularly combinations of sumatriptan and Trixemet® (naproxen). Recent systematic reviews have shown that sumatriptan–naproxen is more effective than placebo and sumatriptan or naproxen alone regarding pain free and pain relief. Compared to their usual migraine therapy, patients found the combination of sumatriptan–naproxen to be superior in decreasing headache severity, lessening associated symptoms, and providing long-lasting relief with a high rate of complete relief with a single dose (60.04% of attacks resolved at 2 hours post treatment). The use of sumatriptan–naproxen is associated with rapid and consistent restoration of patients’ functioning, faster recovery time in some measures of cognitive efficiency, and consistent reduction in productivity loss compared to placebo. In general, combination therapy has higher satisfaction ratings.

The combination of another triptan, frovatriptan 2.5 mg, with two doses of a different NSAID, dexketoprofen 25 and 37.5 mg, has been tested for the therapy of acute migraine. Compared to frovatriptan alone, the group treated with the combination therapy had a significantly higher pain-free rate at 2 and 4 hours and sustained pain-free rate at 24 hours, with no statistically significant difference between participants treated with the dexketoprofen 25 or 37.5 mg combination. Sustained pain-free rate at 48 hours and recurrence of migraine were similar between the three groups, meaning a lack of improvement with the combination therapy.

Recently, a multicenter, randomized, double-blind trial evaluated the efficacy and safety of the combination of sumatriptan 50 mg plus an antiemetic agent promethazine 25 mg. Significantly more patients receiving the combination therapy experienced 2- and 4-hour pain-free response and headache improvement response compared to those treated with sumatriptan alone. In addition, the incidence of headache recurrence within 2–48 hours after treatment was lowest in the sumatriptan–promethazine group. However, significant drug-related AEs were more frequent with combination therapy than with sumatriptan alone (somnolence in 32.2% and 7% patients and extrapyramidal symptoms in 4.3% and 0% patients, respectively), while nausea was more frequent with triptan therapy alone (1% and 8% patients, respectively).

New formulations and device
Triptans are generally effective for migraine treatment but share one problem common to all oral drugs, the delayed absorption of the drug depending on the gastric stasis that occurs during the migraine attacks. This issue has led to the development of new administration routes and devices. Two Cochrane database systematic reviews have focused on intranasal and suppository sumatriptan. Both the formulations have been effective in treating the attack, alleviating migraine-associated symptoms, and restoring functional disability.

A randomized, active-comparator, double-dummy, crossover, multi-attack study (COMPASS study) compared the efficacy and tolerability of AVP-825, a bidirectional breath-powered intranasal delivery system containing low-dose (22 mg) sumatriptan powder vs. oral sumatriptan 100 mg. Rates of pain relief and pain freedom at 2 hours and sustained pain freedom from 2 to 48 hours were similar, but at earlier time point, measured between 15 and 90 minutes, AVP-825 was superior. Nasal discomfort and abnormal taste were more common with AVP-825, while atypical sensation rates were significantly lower than with conventional sumatriptan 100 mg. A post hoc analysis found that AVP-825, compared to oral sumatriptan, led to a more rapid early reduction in overall nausea rate during the first hour, a reduced odds of nausea from 30 minutes to 2 hours following treatment, and a reduced risk of treatment-emergent nausea.

Until recently, the subcutaneous administration route was dependent upon a needle-based mechanism. A needle-free subcutaneous sumatriptan is a nitrogen pressure subcutaneous delivery system approved for the acute treatment of migraine and cluster headache in the US and some European countries. A single dose of needle-free subcutaneous sumatriptan 6 mg demonstrated bioequivalence to a single dose of traditional, needle-based subcutaneous sumatriptan 6 mg when delivered into the abdomen or the thigh, but not into the arm, conferring relief as early as 10 minutes after dosing, whereas oral, rectal, and intranasal routes of administration do so in ~1 hour.

In an open-label, multicenter study, sumatriptan was self-administered by patients currently treated with triptans and less than very satisfied with their acute migraine therapy. The efficacy results were consistent with those previously
observed with needle-based sumatriptan, but participants experienced a statistically significant and clinically relevant increase in satisfaction with therapy and enhanced confidence in treatment after use.

An alternative to current formulations is transdermal drug delivery, particularly iontophoresis. NP101® or Zecuity (formerly known as the Zelrix Migraine Patch) is a transdermal sumatriptan iontophoretic patch designed to release 6.5 mg of sumatriptan (comparable to subcutaneous 6 mg) over 4 hours by using low-level electrical energy to transport sumatriptan across the skin. In double-blind, randomized, placebo-controlled trials, transdermal sumatriptan was superior to placebo but had a generally low clinical efficacy (18% vs placebo) across the skin. The patch is currently removed from the US market after postmarketing reports of application site reactions described as burns and scars.

CGRP targeting drugs
So far, no more recent acute antimigraine treatments have succeeded in passing all developmental stages. Small-molecule CGRP receptor antagonists, the so-called gepants, have been studied since the early 2000s and were promising attack therapies until few years ago. Despite positive Phase II and III trials demonstrating safety and efficacy, their development was terminated. Intravenous olecegaptan (BBN4096BS) was terminated because of difficulty developing an oral formulation, oral telcagepant (MK-0974) and MK-3207 were terminated for transaminase elevation, and BMS-927711, which did not show evidence of hepatotoxicity, was discontinued in 2012 for unknown reasons.

The development of small-molecule CGRP receptor antagonists that seemed abandoned has resumed in 2015 when Allergan purchased the rights of ubrogepant (MK-1602) from Merck. In a completed Phase IIb dose-finding study, ubrogepant doses of 25, 50, and 100 mg were superior to placebo for the 2-hour pain freedom end point, showing a dose-dependent response. Triptan-associated AEs were not observed, and only nausea and dizziness were more common in the ubrogepant group than in the placebo group. Although there was no signal of transaminase elevation, subjects only received a single dose. A second Phase IIb pharmacokinetic study was recently completed, but results have not yet been published. There are two ongoing Phase III RCTs (NCT02867709 and NCT02867709) expected to be completed in March 2018. In both studies, subjects were randomized to treat a single migraine attack either with placebo or with one of two doses of ubrogepant (25 or 50 mg in the first study and 50 or 100 mg in the other study).

Lasmiditan overview

Chemistry
The first 5-HT1F receptor agonist to be tested was LY334370. This compound, while preserving the typical triptan indole core, showed a high selectivity for 5-HT1F (100-fold selectivity for 5-HT1B and 5-HT1D receptors) and also for 5-HT1A receptors. Even so, its development was discontinued because of long-term safety concerns in animals. Therefore, a new selective 5-HT1F receptor agonist was developed changing the chemical structure of LY334370 by replacing the indole moiety with a pyridinyl-piperidine scaffold. Lasmiditan, formerly known as COL-144 and LY573144, is a novel 5-HT receptor agonist with high affinity and selectivity for the 5-HT1F receptor. Its chemical structure is more different from triptans than its predecessor LY334370 and accounts for its inclusion in a new drug class called ditans (Figure 1).

Pharmacodynamics
LY334370 showed relative selectivity for 5-HT1F receptor (100-fold selectivity for 5-HT1F receptors than for 5-HT1B and 5-HT1D receptors) and a substantial affinity for the 5-HT1A receptor. However, a concern rose about the possibility that plasma levels in the therapeutic range might be high enough to activate vascular 5-HT1A receptors. Lasmiditan met the goal of developing a highly selective agonist for the 5-HT1F receptor, structurally different from the triptans, with a greater 5-HT1F receptor selectivity than LY334370 and with minimized interactions with 5-HT1A, 5-HT1B, and 5-HT1D receptors to avoid potential concerns arising for its predecessor. In vitro binding studies showed a 450-fold higher selectivity and higher affinity for 5-HT1F receptors than for 5-HT1A, 5-HT1B, and 5-HT1D receptors, and a low cross-reactivity with other members of the 5-HT1 receptor family, even if all of them are structurally homologous. Moreover, lasmiditan showed no significant affinity across a panel of receptors that are known to regulate vascular tone, the monoaminergic subtypes.

In addition to targeting peripheral 5-HT1F receptors, lasmiditan, being a high lipophilic substance, is able to penetrate the BBB and may act on centrally located receptors. This hypothesis is supported by the results of two animal models of migraine involving electrical stimulation of the trigeminal ganglion that are considered predictive for drug efficacy in acute migraine treatment. Oral administration of lasmiditan at a dose of 3 mg/kg blocked neurogenic inflammation through inhibition.
Serotonin receptor agonists in the acute treatment of migraine

of dural plasma protein extravasation and reduced expression of a proto-oncogene (c-Fos) in the trigeminal nucleus caudalis. The selective functional activity of lasmiditan was demonstrated in vitro in cells expressing the human isoforms of the subtypes of the 5-HT1 receptors using a standard radioligand-binding assay ([35 S]-GTP  \gamma S). While triptans had high potency and efficacy at human 5-HT1B and 5-HT1D receptors, lasmiditan showed low potency at the vasoconstrictor 5-HT1B receptors. Moreover, lasmiditan (in doses up to 100 \mu M) did not cause vessel contraction in the rabbit saphenous vein, which is a surrogate model that predicts vasoconstriction in human coronary arteries. In contrast, sumatriptan led to a 50% vasoconstriction.

Because of the high selectivity for the 5-HT1F receptors and the absence of vasoconstrictive effects, 5-HT1F receptor agonists are considered a new drug category, the neurally acting anti-migraine agent (NAAMA), acting through a unique and promising new antimigraine mechanism.

Pharmacokinetics and metabolism

Lasmiditan has a mean oral bioavailability reported to be \(\sim 40\%\), and the maximum serum concentration of lasmiditan is reached between 1.5 and 2.5 hours (Tmax) after oral administration of 50–400 mg. There are no available data about the possible influence of gender and age on these parameters. A recent randomized, open-label study evaluated the relative bioavailability of lasmiditan (Table 1). The maximum serum concentration (Cmax), Tmax, and the area under the curve (AUC) of lasmiditan 200 mg under fasted and fed conditions were evaluated in 30 healthy subjects. Cmax was, respectively, 322.8±122.0 and 394.7±167.8 ng/mL (mean±SD); Tmax was, respectively, 1.5±1.0 and 2.5±1.0 hours (mean±SD); and AUC0–t was, respectively, 1892±746.0 and 2244±926.2 ng×h/mL (mean±SD). There are no data about lasmiditan half-life (t1/2) and metabolism; therefore, the existence of active and/or inactive metabolites is unknown.
The efficacy of the intravenous formulation without severe AEs. Peer-reviewed publications for the Phase I trials do not exist. In each of these studies, 40–55 healthy subjects were evaluated to test the safety, tolerability, pharmacodynamics, and pharmacokinetics of lasmiditan.

The first Phase I trial was performed in 2003 to evaluate safety, tolerability, and pharmacokinetics of intravenous administration of lasmiditan (no published data available). In 2008, two Phase I trials (COL MIG-102 and COL MIG-103) tested different oral formulations (oral solution, oral tablet, and sublingual) to evaluate their safety, tolerability, bioavailability, and other pharmacokinetic parameters. Oral formulations demonstrated to reach plasma levels associated with efficacy of the intravenous formulation without severe AEs. The oral formulation dose at least effective as sumatriptan in acute migraine treatment was calculated to be ≥170 mg.

In 2011, the Phase I study COL MIG-105 evaluated the cardiac safety of lasmiditan. This randomized, double-blind study compared the effects on cardiac depolarization and repolarization duration and other cardiac safety parameters of oral lasmiditan (100 and 400 mg) with those of the antibiotic moxifloxacin (400 mg) and placebo. Lasmiditan at both doses did not cause QT prolongation compared to moxifloxacin that led to QT prolongation as seen in other published studies. Moreover, no arrhythmia or any proarrhythmic effects were reported with lasmiditan.

The last Phase I study investigated the effects of the fed and fasted states on pharmacokinetic parameters (Cmax, Tmax, AUC) and AEs. The fed condition was associated with an increase in Cmax, Tmax, and AUC and a lower rate of mild AEs. Several Phase I clinical trials are currently undergoing, while others have been recently completed, but the results are not yet available (Table 2).

### Phase II clinical trials

Two Phase II trials were conducted in 2007 and 2009 for the intravenous formulation and the oral formulation, respectively.

The first study was a proof-of-concept and dose-finding, multicenter, randomized, double-blind, placebo-controlled trial that enrolled 130 migraine patients with a migraine history of ≥1 year and not taking prophylactic medication. The adaptive treatment design of the study allowed the up-or down-titration of the study drug (either lasmiditan i.v. in doses of 2.5–45 mg or placebo) according to efficacy and AEs. The primary efficacy measure was headache response (improvement from moderate or severe headache to mild or no headache) at 2 hours. Better response was observed in the groups receiving lasmiditan compared to placebo (54.2%–75% vs. 45.2%) with a significant dose–response relationship with increasing doses of lasmiditan and with doses of ≥20 mg being more effective. For lasmiditan 20 mg, the headache response was 64% with a therapeutic gain (percentage difference between active drug and placebo) of 19%. Accordingly, the use of rescue medication decreased while patients’ global impression improved significantly with the increasing dose. The onset of pain relief occurred in 20–40 minutes.

The second Phase II study was a dose-ranging, multicenter, randomized, double-blind, placebo-controlled trial that enrolled 534 migraine patients with a migraine history of ≥1 year and not taking prophylactic medication. Patients were randomized to treat one migraine attack with a rapid disintegration tablet of lasmiditan (in doses of 50, 100, 200, and 400 mg) or placebo in a 1:1:1:1:1 ratio. Every lasmiditan dose was superior to placebo for the primary efficacy measure (headache response at 2 hours) with a significant linear dose–response association. After 1 hour, all the doses, except the 50 mg dose, were superior to placebo, and the 400 mg dose significantly reduced headache severity starting as early as 30 minutes, and after 90 minutes, all groups reached statistical significance vs. placebo. The therapeutic gains for headache responses at 2 hours were 18%, 38%, 29%, and 39% for 50, 100, 200, and 400 mg of lasmiditan, respectively, compared to placebo. The therapeutic gain of lasmiditan 400 mg (39%) was higher than that of the intravenous 20 mg, probably because of the dose difference (oral 400 mg corresponds to i.v. dose of −160 mg).

### Phase III clinical trials

Five Phase I studies have been conducted for lasmiditan (four for the oral formulation and one for the intravenous formulation). Peer-reviewed publications for the Phase I trials do not exist. In each of these studies, 40–55 healthy subjects were evaluated to test the safety, tolerability, pharmacodynamics, and pharmacokinetics of lasmiditan. The second Phase II study was a dose-ranging, multicenter, randomized, double-blind, placebo-controlled trial that enrolled 534 migraine patients with a migraine history of ≥1 year and not taking prophylactic medication. The primary efficacy measure was headache response (improvement from moderate or severe headache to mild or no headache) at 2 hours. Better response was observed in the groups receiving lasmiditan compared to placebo (54.2%–75% vs. 45.2%) with a significant dose–response relationship with increasing doses of lasmiditan and with doses of ≥20 mg being more effective. For lasmiditan 20 mg, the headache response was 64% with a therapeutic gain (percentage difference between active drug and placebo) of 19%. Accordingly, the use of rescue medication decreased while patients’ global impression improved significantly with the increasing dose. The onset of pain relief occurred in 20–40 minutes.

The second Phase II study was a dose-ranging, multicenter, randomized, double-blind, placebo-controlled trial that enrolled 534 migraine patients with a migraine history of ≥1 year and not taking prophylactic medication. Patients were randomized to treat one migraine attack with a rapid disintegration tablet of lasmiditan (in doses of 50, 100, 200, and 400 mg) or placebo in a 1:1:1:1:1 ratio. Every lasmiditan dose was superior to placebo for the primary efficacy measure (headache response at 2 hours) with a significant linear dose–response association. After 1 hour, all the doses, except the 50 mg dose, were superior to placebo, and the 400 mg dose significantly reduced headache severity starting as early as 30 minutes, and after 90 minutes, all groups reached statistical significance vs. placebo. The therapeutic gains for headache responses at 2 hours were 18%, 38%, 29%, and 39% for 50, 100, 200, and 400 mg of lasmiditan, respectively, compared to placebo. The therapeutic gain of lasmiditan 400 mg (39%) was higher than that of the intravenous 20 mg, probably because of the dose difference (oral 400 mg corresponds to i.v. dose of −160 mg).

The first study was a proof-of-concept and dose-finding, multicenter, randomized, double-blind, placebo-controlled trial that enrolled 130 migraine patients with a migraine history of ≥1 year and not taking prophylactic medication. The adaptive treatment design of the study allowed the up-or down-titration of the study drug (either lasmiditan i.v. in doses of 2.5–45 mg or placebo) according to efficacy and AEs. The primary efficacy measure was headache response (improvement from moderate or severe headache to mild or no headache) at 2 hours. Better response was observed in the groups receiving lasmiditan compared to placebo (54.2%–75% vs. 45.2%) with a significant dose–response relationship with increasing doses of lasmiditan and with doses of ≥20 mg being more effective. For lasmiditan 20 mg, the headache response was 64% with a therapeutic gain (percentage difference between active drug and placebo) of 19%. Accordingly, the use of rescue medication decreased while patients’ global impression improved significantly with the increasing dose. The onset of pain relief occurred in 20–40 minutes.
### Table 2 Summary of completed and ongoing Phase I clinical trials on lasmiditan

<table>
<thead>
<tr>
<th>ID number</th>
<th>Study name</th>
<th>Primary outcome measures</th>
<th>Completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03247790</td>
<td>An open-label, two-period study to evaluate the pharmacokinetics of lasmiditan in migraineurs during acute migraine attacks and during inter-ictal periods</td>
<td>$C_{\text{max}}$ of lasmiditan in each period AUC (0–∞) of lasmiditan in each period</td>
<td>March 2018</td>
</tr>
<tr>
<td>NCT03270644</td>
<td>Effect of lasmiditan on the heart rate and blood pressure in healthy subjects receiving oral doses of propranolol</td>
<td>Change in mean hourly heart rate as determined by Holter ambulatory monitoring</td>
<td>November 2017</td>
</tr>
<tr>
<td>NCT03182920</td>
<td>Effect of age on the pharmacokinetics, safety, and tolerability of lasmiditan in healthy subjects</td>
<td>$C_{\text{max}}$ of major lasmiditan metabolites in each period AUC (0–∞) of major lasmiditan metabolites in each period</td>
<td>August 2017</td>
</tr>
<tr>
<td>NCT03040362</td>
<td>A Phase I study to investigate the absorption, metabolism, and excretion of [14C]-lasmiditan following single oral dose administration in healthy male and female subjects</td>
<td>$C_{\text{max}}$ based on plasma concentrations of lasmiditan $T_{\text{max}}$ based on plasma concentrations of lasmiditan AUC from hour 0 to the last measurable concentration based on plasma concentrations of lasmiditan AUC (0–∞) of total radioactivity in blood/AUC (0–∞) of total radioactivity in plasma AUC (0–∞) of lasmiditan in plasma/AUC (0–∞) of total radioactivity in plasma</td>
<td>May 2017</td>
</tr>
<tr>
<td>NCT03009162</td>
<td>A Phase I, multicenter, open-label, parallel-group adaptive pharmacokinetic single dose study of oral lasmiditan in subjects with normal and impaired renal function</td>
<td>$C_{\text{max}}$ based on plasma concentrations of lasmiditan $T_{\text{max}}$ based on plasma concentrations of lasmiditan AUC (0–∞) Amount excreted in urine Fraction of dose excreted in urine Renal clearance</td>
<td>June 2017</td>
</tr>
<tr>
<td>NCT03308669</td>
<td>Safety, tolerability, and pharmacokinetics of lasmiditan when coadministered with topiramate in healthy subjects</td>
<td>Number of participants with one or more SAEs considered by the investigator to be related to study drug administration</td>
<td>December 2017</td>
</tr>
<tr>
<td>NCT03310411</td>
<td>A randomized, double-blind, four-period, crossover study to evaluate the cardiovascular effect of single oral doses of lasmiditan when coadministered with single oral doses of sumatriptan in healthy subjects</td>
<td>SBP per 24-hour ABPM</td>
<td>December 2017</td>
</tr>
<tr>
<td>NCT03286218</td>
<td>A randomized, subject- and investigator-blind, placebo- and active-controlled study to assess the abuse potential of lasmiditan</td>
<td>Change from baseline in $E_{\text{max}}$ of bipolar drug liking VAS scores</td>
<td>November 2017</td>
</tr>
<tr>
<td>NCT03252015</td>
<td>Multiple-ascending dose, safety, tolerability, pharmacokinetic, and drug–drug interaction study of lasmiditan</td>
<td>Number of participants with one or more SAEs considered by the investigator to be related to study drug administration</td>
<td>January 2018</td>
</tr>
<tr>
<td>NCT03076970</td>
<td>A randomized, double-blind, three period, crossover study to evaluate the effect of single oral doses of lasmiditan when coadministered with single oral doses of sumatriptan (Imitrex) in healthy male and female subjects</td>
<td>Change from pre dose to 24 hours in vital signs Change from pre dose to 24 hours in ECGs AEs</td>
<td>April 2017</td>
</tr>
<tr>
<td>NCT03040479</td>
<td>A Phase I, multicenter, open-label, parallel-group, pharmacokinetic single dose study of oral lasmiditan in subjects with normal and impaired hepatic function</td>
<td>$C_{\text{max}}$ based on plasma concentrations of lasmiditan $T_{\text{max}}$ based on plasma concentrations of lasmiditan AUC (0–∞) Apparent elimination rate constant Terminal elimination half-life</td>
<td>July 2017</td>
</tr>
<tr>
<td>NCT03012334</td>
<td>A Phase I, randomized, double-blind, placebo-controlled, five-period, cross-over study assessing the effects of lasmiditan on simulated driving performance in normal healthy volunteers</td>
<td>Simulated driving performance in healthy subjects as measured by SDLP using the CRCDS-MiniSim</td>
<td>June 2017</td>
</tr>
</tbody>
</table>

**Notes:** $C_{\text{max}}$, maximum observed concentration; AUC (0–∞), area under the concentration vs. time curve from zero to infinity; $T_{\text{max}}$, time to maximum concentration; $E_{\text{max}}$, maximal effect score. Data from clinicaltrials.gov.

**Abbreviations:** SAE, serious adverse event; SBP, systolic blood pressure; ABPM, ambulatory blood pressure monitoring; VAS, visual analog scale; ECG, electrocardiogram; AE, adverse event; SDLP, standard deviation of lateral position; CRCDS-MiniSim, Cognitive Research Corporation’s driving simulator-MiniSim.
response with 100 mg was superior to 200 mg and was similar to 400 mg. The reason may depend on the small sample sizes and the random variation in severity and response of migraine attacks. The therapeutic gains for headache responses of lasmiditan 100 mg (38%) and 400 mg (39%) are in the same range of oral triptans.8 Lasmiditan doses of 200 and 400 mg were superior to placebo (19% and 28% vs. 7.4%) for pain free at 2 hours (secondary end point), but lasmiditan 100 mg (14%) was not. Both doses of lasmiditan, 100 and 400 mg, were superior to placebo for improvements in headache severity, clinical disability, headache recurrence within 24 hours, and patients’ global impression of treatment.

**Phase III clinical trials**
Currently, two Phase III clinical trials and one long-term, open-label study are ongoing.63–65

The first trial is a randomized, double-blind, placebo-controlled parallel group study (COL MIG-301 or SAMURAI, ID number NCT02439320) evaluating the efficacy of two doses of lasmiditan (100 and 200 mg) for the outpatient treatment of one migraine attack. A second dose within 24 hours was allowed for rescue or recurrence of migraine.63 For this study, 2232 patients older than 18 years (with no upper age limit) with episodic disabling migraine (assessed by the Migraine Disability Assessment score ≥11) were enrolled. The primary and secondary end points were the proportion of subjects with pain-free headache and the proportion of subjects who were free of most bothersome migraine-associated symptoms at 2 hours post dose. The most bothersome migraine-associated symptom (identified by the subjects among nausea, photophobia, and phonophobia) is a new end point never used before in migraine therapy. Other outcome measures were headache relief (at 2 hours); use of rescue medication (at 2 hours and 2–24 hours); headache recurrence (within 48 hours); proportion of patients who were free of nausea, photophobia, and phonophobia (at 2 hours); AEs (up to 11 weeks); and health care resource utilization (6 months prior to enter in the study compared with its use during the time on study). Both doses showed superiority compared to placebo for the primary and several secondary end points with statistical significance.

The second trial is a randomized, double-blind, placebo-controlled parallel group study (COL MIG-302 or SPARTAN, ID number NCT02605174) evaluating the efficacy of three doses of lasmiditan (50, 100, and 200 mg) for the outpatient treatment of one migraine attack.64 The characteristics of the enrolled population (3007 subjects), the design, and the end points of this study were same as of the SAMURAI trial.

The long-term, open-label trial of lasmiditan (COL MIG-305 or GLADIATOR, ID number NCT02565186) started in October 2015 and is estimated to end in May 2018.65 This is a prospective, randomized, open-label study of subjects with migraine who have completed SAMURAI or SPARTAN. The study is designed to evaluate the safety and tolerability (primary end point) of long-term (12 months) intermittent use of lasmiditan 100 and 200 mg as the first dose and the second dose for the acute treatment of migraine. Long-term efficacy (secondary end point) will also be evaluated, as well as the 12-month health care resource utilization.

**Clinical safety and tolerability**
In all studies, lasmiditan did not show the usual side effects of triptans. Typical triptan-associated AEs (chest or neck pain, tightness, or heaviness) were rare and with a rate similar to the placebo-treated groups.56,62 This finding was expected considering the different chemical structure of lasmiditan.

Most importantly, cardiac safety of lasmiditan was confirmed as no arrhythmia or any proarrhythmic effects were observed.61 No pathological abnormalities of any safety parameters (i.e., vital parameters, 12-lead electrocardiogram [ECG], hematology, biochemistry, and urine analysis) were reported following the administration of lasmiditan, for both the intravenous and oral formulations (all doses up to 400 mg).56,62

However, this selective 5-HT1<sub>1</sub> receptor agonist showed a high incidence of the central nervous system (CNS)-related AEs, probably because of the high CNS permeability through the BBB. In one Phase I study, the most common side effect was somnolence,58 while in another study, drowsiness, dizziness, and paresthesia were reported as the most frequent AEs with the maximum dose of 400 mg.59 In the first Phase II trial with the intravenous formulation (20 mg), 65% of subjects on lasmiditan and 43% on placebo reported mild AEs, and the most common were paresthesia, dizziness, and limb heaviness.62 The rate of placebo-subtracted AEs for lasmiditan was 25%.

The larger human safety and tolerability data came from the oral lasmiditan Phase II study (Table 3).56 AEs of dizziness, paresthesia, vertigo, fatigue, and somnolence were reported by 22% of the patients receiving placebo and, in a dose-dependent manner, by 65%, 72%, 86%, and 84% of patients receiving lasmiditan (50, 100, 200, and 400 mg, respectively). The rate of placebo-subtracted AEs was 50% for oral lasmiditan 100 mg and was 66% for lasmiditan 400 mg. Most AEs were mild. However, with lasmiditan 100 mg, moderate and severe AEs were reported by 46% and 27% of patients. At the dose of 400 mg, 60% of subjects...
reported moderate AEs and 44% of subjects reported severe AEs. Thus, almost one-third of patients experienced severe CNS-related AEs even with the 100 mg dose. A 46-year-old woman had an overnight hospital admission for moderate dizziness occurring 30 minutes after taking 200 mg of lasmiditan. ECGs showed sinus bradycardia 1.5 and 4 hours after drug intake but no other abnormalities. She received a saline infusion and had complete recovery by the next day. The AE was classified as serious.

In the first Phase III trial (SAMURAI study), lasmiditan was tolerated and, as in the Phase II studies, most AEs were related to the CNS or the vestibular system.66 The most common side effect was dizziness (11.9% and 15.4% for lasmiditan 100 and 200 mg, respectively, vs. 3.1% for placebo). Other common AEs were paresthesia, nausea, somnolence, and fatigue. AEs were reported to be mild or moderate in 91% of the cases, and some of them (dizziness and vertigo) occurred less frequently than those observed in the Phase II trials.

### Migraine pathophysiology: how does an acute treatment work?

The pathophysiology of migraine still remains not completely clear, but the current view considers this primary headache as a disorder in which the brain, meningeal blood vessels, and the trigeminal nerve system play a crucial role.67 The current standard pharmacotherapies have been developed when migraine was believed to be primarily a vascular disease depending on the abnormal vasodilation of intracranial vessels.68 Hence, it was supposed that constriction of dilated cerebral blood vessels could block a migraine attack.

Although the vascular hypothesis was reinforced by the efficacy of 5-HT1 receptors (triptans), which act as potent cerebral vasoconstrictors, it has been overtaken by the neurogenic hypothesis. Recent experimental evidences suggest that migraine is primarily a neuronal disease.67,69,70 According to this model, cranial vasodilation is not the primum movens but only an epiphenomenon in migraine pathophysiology. The primary cause is supposed to be the activation and sensitization of the trigeminal nerve system innervating the large vessels in the meninges.71 These processes lead to neuuropeptide release, particularly CGRP, which is a well-known vasodilator, and a subsequent increase in vessel diameter and blood flow in the meninges and cortex. In the cascade of events, the following excitation of secondary and tertiary central trigeminal neurons may activate cortical and subcortical areas, giving a reason to the pain and other typical migraine symptoms.72

Triptans may act also through neural mechanisms, more likely inhibiting neuuropeptide release (i.e., CGRP) from trigeminal neurons and consequently blocking transmission of pain signals within the trigeminal cervical complex.72 The neurogenic hypothesis implies the possibility that vasoconstriction is not essential for antimigraine therapy and that migraine may be aborted inhibiting central or peripheral nervous system mechanisms. In this view, CGRP receptor antagonists (gepants) seemed to be promising alternatives to triptans, but, even if effective, their development was interrupted because of the concern regarding hepatotoxicity.72

Recently, 5-HT1 receptors, expressed by trigeminal neurons, trigeminal ganglion, and trigeminal nucleus caudalis and lacking vasoconstrictive effects, were thought as an ideal target for migraine abortive drug development.75,76 Specifically, lasmiditan has a peculiar and unique chemical structure that avoids typical triptans-related side effects (e.g., neck, jaw, and chest symptoms) and makes it able to cross the BBB and act both centrally on trigeminal neurons and

### Table 3 Treatment-emergent and severe AEs after placebo and oral lasmiditan (50–400 mg)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Placebo (n=19/86; 22%)</th>
<th>Lasmiditan 50 mg (n=53/82; 65%)</th>
<th>Lasmiditan 100 mg (n=59/82; 72%)</th>
<th>Lasmiditan 200 mg (n=61/71; 86%)</th>
<th>Lasmiditan 400 mg (n=59/70; 84%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dizziness</td>
<td>0 (0%)</td>
<td>19 (23%)</td>
<td>21 (26%)</td>
<td>27 (38%)</td>
<td>26 (37%)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>2 (2%)</td>
<td>10 (12%)</td>
<td>17 (21%)</td>
<td>15 (21%)</td>
<td>16 (23%)</td>
</tr>
<tr>
<td>Vertigo</td>
<td>1 (1%)</td>
<td>8 (10%)</td>
<td>12 (15%)</td>
<td>12 (17%)</td>
<td>16 (23%)</td>
</tr>
<tr>
<td>Somnolence</td>
<td>2 (2%)</td>
<td>10 (12%)</td>
<td>10 (12%)</td>
<td>8 (11%)</td>
<td>8 (11%)</td>
</tr>
<tr>
<td>Paresthesia</td>
<td>2 (2%)</td>
<td>2 (2%)</td>
<td>2 (2%)</td>
<td>2 (2%)</td>
<td>2 (2%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>0 (0%)</td>
<td>4 (5%)</td>
<td>8 (10%)</td>
<td>2 (2%)</td>
<td>3 (4%)</td>
</tr>
<tr>
<td>Sensation of heaviness</td>
<td>1 (1%)</td>
<td>4 (5%)</td>
<td>8 (10%)</td>
<td>0 (0%)</td>
<td>5 (7%)</td>
</tr>
</tbody>
</table>

**Note:** The first row reports the occurrence rate (%) of treatment-emergent events calculated as the ratio between subjects experiencing an AE (n) and the total population in each treatment group. Modified from Lancet Neurol, 11(5) Farkkila M, Diener HC, Geraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study, 405–413, Copyright (2012), with permission from Elsevier.14

**Abbreviation:** AE, adverse event.
peripherally on primary trigeminal afferents and cell bodies within the trigeminal ganglion.77

In Phase II and III trials, lasmiditan proved to be an effective acute treatment for migraine attacks with an AE profile exclusively related to CNS, depending on its penetration through the BBB. By stimulation of the 5-HT1F receptors, lasmiditan may inhibit central and peripheral neuronal activities and the neuropeptide release (e.g., CGRP), thereby terminating acute migraine.75,78,79 Because of this mechanism of action and the absence of vasoconstrictor activity, lasmiditan is considered the first of the new drug class, the NAAMAs.

Lasmiditan has a high selectivity for the 5-HT1F receptors, which cannot be found on endothelial or smooth muscle cells of cerebral vessels.80 Moreover, its binding profile avoids potential AEs of the activation of 5-HT1B receptors in peripheral blood vessels, particularly the coronary arteries.10,69 Based on its lack of vasoconstriction, this substance could serve as a treatment option for subjects with cardiovascular diseases to whom triptans are contraindicated.

Expert opinion

Conclusion

Almost 30 years have passed since the introduction of triptans. They represented a major breakthrough in the acute treatment of migraine but are contraindicated in patients with previous cardio- and cerebrovascular diseases and in those with uncontrolled hypertension. Unfortunately, a high percentage of patients are not satisfied with this acute treatment, either for lack of response or for side effects. Since their introduction, no other acute drug class has passed all developmental stages.

Lasmiditan is a new effective drug with no vasoconstrictive action and a CNS-related AE profile.

There are some open questions that hopefully will find answers in future studies.

First of all, the serious matter of medication overuse headache (MOH).81 The pathophysiology of MOH is largely unknown, but both human and animal studies suggest modifications of the pain network. An excessive use of any of the acute drug classes (either specific or not) can cause headache to worsen and increase in frequency, and become less responsive to both acute and preventative medications.82 This leads to a vicious circle that is sometimes difficult to break. For triptans (5-HT1F/1B agonists), the cutoff for the overuse is ≥15 days/month (for at least 3 months). Lasmiditan, as triptans, is a 5-HT agonist, but it differs for a unique chemical structure and for a high selectivity for the 5-HT1F subtype. However, there is the possibility that overuse of lasmiditan will lead to MOH. A second important matter is the use of lasmiditan during pregnancy and breastfeeding. This concern is of paramount importance, thinking that migraine is more frequent in women and particularly during the fertile period of their life. Triptans do not seem to increase the rates of major congenital malformations, but children exposed to triptans in utero might have a higher risk of developing externalizing behaviors.17 They are considered probably compatible with breastfeeding. Lasmiditan, as triptans, is a high lipophilic molecule that in Phase II and III studies showed a safety profile different from the 5-HT1F/1B agonists, with most of the AEs being related to CNS. This could limit their use during pregnancy and breastfeeding.

Future Phase III clinical trials will determine whether lasmiditan will become available in the market, and then active triptan comparator studies will assess patients’ preference.

Disclosure

The authors report no conflicts of interest in this work.

References


44. Freitag FG. Sumatriptan needle-free subcutaneous (Sumavel® DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches. Expert Rev Neurother. 2011;11(4):481–490.


